Wed, Oct 18, 2023
CorporateRadar, Demand trend of large pharma strong, Demand trend of small pharma will improve in 1-2 quarters. Acquired Stelis Biopharma last quarter, Mahesh Bhalgat. Watch Swati Khandewal's exclusive conversation with Mahesh Bhalgat, COO of Syngene International.
More >
Syngene International trimmed its revenue growth guidance to mid-teen levels in constant currency terms for the six-month period ending March 2024, sending its shares tumbling.
Thu, Jul 27, 2023
Due to strong demand, expect good performance in future, will spend funds on new acquisitions, capacity expansion: Dr. Mahesh Bhalgat, COO, Syngene International
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
